Profound Medical Reports Record Q4 Revenue, Strong Pipeline Growth, and Appoints Medical Device Veteran to Board

summarizeSummary

Profound Medical reported record Q4 and full-year 2025 revenue, alongside significant business expansion, product innovation, and the appointment of a highly experienced medical device executive to its board, despite increased net losses.

check_boxKey Events

• Record Revenue Growth Reported

  Profound Medical achieved record Q4 2025 revenue of $6.0 million, a 43% year-over-year increase, and full-year 2025 revenue of $16.1 million, up from $10.7 million in 2024. Gross margin for the full year improved to 71%.

• Significant Business Expansion and Product Innovation

  The TULSA-PRO installed base reached 78 systems, with an expected growth to approximately 120 by the end of 2026, supported by a qualified sales pipeline of 110 new systems. The company launched its TULSA-AI Volume Reduction module, which is anticipated to triple the total available market for prostate disease treatment to about 600,000 patients annually. New distribution agreements were established in Saudi Arabia, Australia, and New Zealand, alongside regaining Canadian rights.

• Major Commercial Milestones and Upcoming Clinical Data

  Johns Hopkins Hospital and Mount Sinai Hospital successfully launched the TULSA-PRO system in January 2026. The first clinical outcomes from the Level 1 post-market CAPTAIN trial, comparing TULSA Procedure with robotic radical prostatectomy, are scheduled for presentation at the European Association of Urology Congress on March 13, 2026.

• Highly Experienced Executive Appointed to Board

  Kris Shah resigned from the Board of Directors, and Frank Baylis was appointed as his successor. Mr. Baylis is a successful entrepreneur and former President of Baylis Medical Company, which was acquired by Boston Scientific for $1.75 billion, bringing significant medical device industry expertise to the board.

auto_awesomeAnalysis

Profound Medical Corp. reported strong revenue growth for both Q4 and the full year 2025, driven by increased capital equipment sales and recurring revenue. While net losses widened due to increased operating expenses for growth initiatives, the company's cash position remains robust, bolstered by a recent $42.45 million financing. Key business highlights include a growing TULSA-PRO sales pipeline, significant commercial milestones with major hospitals like Johns Hopkins and Mount Sinai, and the launch of the TULSA-AI Volume Reduction module, which is expected to triple the total available market for prostate disease treatment. The upcoming presentation of Level 1 CAPTAIN trial results is a major catalyst. Additionally, the appointment of Frank Baylis, a highly successful medical device entrepreneur, to the Board of Directors is a strong positive signal, bringing invaluable experience to support the company's growth strategy.